Navigation Links
BioMS Medical's phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
Date:10/3/2008

Toronto Stock Exchange Symbol: MS

EDMONTON, Oct. 3 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) for the Company's U.S. pivotal phase III MAESTRO-03 trial of dirucotide (MBP8298) in patients with secondary progressive MS has completed a safety analysis and recommended that the trial continue as per the protocol.

This was the third of several regularly scheduled reviews by the DSMB that will occur over the duration of the trial. The purpose of the DSMB is to provide objective, independent safety monitoring of the trial.

About MAESTRO-03

----------------

The MAESTRO-03 U.S. pivotal phase III clinical trial is a randomized, double-blind study that has completed recruitment of approximately 510 patients at 68 clinical sites who will be administered either dirucotide (MBP8298) or placebo intravenously every six months for a period of two years. The primary clinical endpoint for the trial is defined as a statistically and clinically significant increase in the time to progression of the disease as measured by the Expanded Disability Status Scale (EDSS), in patients with HLA-DR2 and/or HLA-DR4 immune response genes (up to 75% of all MS patients are HLA-DR2 and/or HLA-DR4 positive).

About BioMS Medical Corp.

-------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide (MBP8298), is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. In December 2007
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... -- Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology ... to manufacture proteins including biosimilar therapeutics, today announced that ... Annual NewsMakers in the Biotech Industry conference in ... chief executive officer of Pfenex, will provide an overview ... Friday, September 26, 2014 at 10:00 a.m. EDT/7:00 a.m. ...
(Date:9/19/2014)... September 19, 2014 ... http://www.researchandmarkets.com/research/b2jxhs/micro_market ) has announced the addition of the  ...  report to their offering.       (Logo: ... one of the fastest-growing segments in the chromatography ... in 2013, and expected to reach $2.0 billion ...
(Date:9/18/2014)... HealthTronics, Inc ., a leading ... and services, announced that a poster related to ... external beam radiotherapy (EBRT) is being presented at ... (MAAUA) Annual Meeting in Baltimore, Maryland September 18-21, ... and External Beam Radiation as Treatments for Localized ...
(Date:9/18/2014)... Mich. , Sept. 18, 2014  Health Enhancement Products, ... firm investigating early-stage algae bioactive compounds and metabolic processes, is ... the company,s board of directors. Ms. Nola E. Masterson ... investment advisor joined the board effective September 17, 2014. ... Masterson agree to join our board," states Andrew Dahl ...
Breaking Biology Technology:Pfenex to Present at Upcoming Industry Conference on September 26 2Micro Market Monitor : Global Pre-packed Chromatography Columns 2HealthTronics Announces Data Comparing Cryotherapy Versus Radiation for Treating Prostate Cancer Poster Presented at the American Urological Association Regional Meeting 2Health Enhancement Announces New Board Member In Advance Of Annual Shareholder Meeting 2
... Inc. (Nasdaq: ALTH ), a biopharmaceutical company ... therapeutics for,the treatment of cancer, today announced that ... corporate overview at the Bear Stearns 20th Annual,Healthcare ... will take place at 9:00 a.m. (Eastern) on,Monday, ...
... 4 Medarex, Inc.,(Nasdaq: MEDX ) announced today ... 20th Annual Healthcare Conference at 9:00 AM Eastern Time ... at The Grand Hyatt,New York in New York City. ... for replay through the Webcast page in the Investor,Relations ...
... Statistical Considerations for Model, Selection and Bias; Dr. Klaas Prins ... ... Using Metadata, MOUNTAIN VIEW, Calif., ... provider of software and,strategic services for optimizing clinical drug development, ...
Cached Biology Technology:Allos Therapeutics to Present at the Bear Stearns 20th Annual Healthcare Conference 2Medarex to Present at the Bear Stearns 20th Annual Healthcare Conference 2Pharsight to Present at ROeS Seminar in Bern, Switzerland on September 10 & 11, 2007 2Pharsight to Present at ROeS Seminar in Bern, Switzerland on September 10 & 11, 2007 3
(Date:9/18/2014)... Boulder, Colo., USA Miranda, a small, icy moon ... and enigmatic bodies in the solar system. Despite its ... episode of intense resurfacing that resulted in the formation ... -- polygonal-shaped regions called coronae. , These coronae ... is at least 200 km across. Arden corona, the ...
(Date:9/18/2014)... "frequent flyers" program, fruit flies surely would be eligible ... increasing numbers of fruit fly research studies. One fruit ... and another is scheduled launch to the station Sept. ... December. , Fruit flies are biomedical research models studied ... organisms can reveal the basis for health and disease ...
(Date:9/18/2014)... stored in DNA, tiny strands of nucleic acid that ... express this genetic data, our DNA is copied into ... that perform tasks in our cells. , Several ... molecule. Unlike all other known RNAs, this molecule is ... are abundant, little has been known about how they ...
Breaking Biology News(10 mins):Miranda: An icy moon deformed by tidal heating 2Miranda: An icy moon deformed by tidal heating 3Miranda: An icy moon deformed by tidal heating 4Miranda: An icy moon deformed by tidal heating 5Miranda: An icy moon deformed by tidal heating 6Miranda: An icy moon deformed by tidal heating 7Buzzing with activity: Fruit flies orbit Earth for science 2Buzzing with activity: Fruit flies orbit Earth for science 3Buzzing with activity: Fruit flies orbit Earth for science 4Scientists find how mysterious 'circular RNA' is formed, claim muscular dystrophy link 2
... A study of DNA rearrangements in roundworm chromosomes may offer ... tumors. A report of the research led by University ... was published in the April 22 online edition of the ... region of repetitive DNA sequence that protects the ends of ...
... how a single-celled fungus survives in low-oxygen settings may ... organ transplants or AIDS. A report on the ... 22 in Molecular Cell . Previous work ... model organism that,s often used to study individual genes, ...
... in German . It would appear reasonable ... similar genetic blueprints. However, scientists from the Max Planck Institute ... international research team have now decoded, for the first time, ... lyrata ), a close relative of the thale cress ( ...
Cached Biology News:Study in roundworm chromosomes may offer new clues to tumor genome development 2Simple fungus reveals clue to immune system protection 2Evolution can cause a rapid reduction in genome size 2Evolution can cause a rapid reduction in genome size 3
Request Info...
Tight junctions are complexes of proteins that create intercellular boundaries between the plasma membrane domains of epithelial and endothelial cells. Antigen: Synthetic peptide corresponding to...
TNF-Related Apoptosis Inducing Ligand-Receptor-1...
NATIVE PORCINE COLIPASE...
Biology Products: